Close Menu

NEW YORK — Horizon Discovery Group reported on Monday a 14 percent year-over-year drop in revenues for the first half of 2020 as a reduction in academic research due to the ongoing SARS-CoV-2 pandemic bit into sales of the company's reagent offerings.

For the six-month period ended June 30, Horizon's revenues fell to £22.4 million ($29.3 million) from £26.1 million a year earlier. On a constant currency basis, the gene editing and gene modulation technologies firm's revenues were down nearly 16 percent to £22.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sponsored by

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Sponsored by

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.